The evolving landscape of drug targets.

Transforming the Landscape of Drug Innovation in AI Era: AlphaFold 3 and Beyond

ABSTRACT The traditional drug discovery and development (DDD) pipeline has long been characterized by inefficiency and high costs. The rapid evolution of artificial intelligence (AI), especially AI‐based toolkits for protein structure and interaction prediction, exemplified by AlphaFold 3 (AF3), promises to reshape the...

Innovation-driven drug discovery: Frontier exploration and breakthrough

The progress of drug discovery to the market typically requires 12 to 15 years, during which substantial financial investments are continuously made for various research and testing activities. The complexity and multifactorial nature of the disease, the complexity of the drug development process, the size of the chemi...

Therapeutic oligonucleotides as genetic medicines: The current state and future perspective

Summary Antisense therapeutic oligonucleotides are entering a transformative era in clinical development, with a total of 21 oligonucleotides approved and a robust pipeline poised for the coming years. These drugs have emerged as a cornerstone of genetic medicine, providing a programmable platform to modulate gene expr...

Small-Molecule Drugs Approved by the FDA in 2025

In today’s pharmaceutical sector, innovation is not only the core driver of industry upgrading, but also closely tied to patient health and well-being. A drug’s innovative mechanism of action, physiological effects, chemical structure, and indications collectively reflect both its clinical therapeutic value and the nov...

Pharmaceuticals has been the Development of Targeted Therapies and Personalized Medicine

Multitarget Drug Design for Cardiovascular Disease: Bridging Chemistry and Medicine

This review provides an overview of recent advances in the development of multitarget drugs (MTDs) for cardiac diseases, with a particular focus on emerging molecular scaffolds and their pharmacological properties. We discuss the fundamental principles of cardiac polypharmacology and multitarget drug design, highlighti...